- Orthocell (OCC) takes the next steps in its license and distribution agreements for its Striate+ dental membrane for bone regeneration
- The exclusive patent and trademark licence agreement and distribution agreement is with Delaware corporation, BioHorizons Implant Systems
- Under the contract, Orthocell will grant BioHorizons an exclusive licence of two patent families, covering a collagen scaffold of cell growth, along with a method for producing a collagen membrane
- Orthocell says the funds from BioHorizons have solidified its cash position, with $31.23 million on hand as of July 20
- Shares in Orthocell are up 3.95 per cent and trading at 39.5 cents at 1:48 pm AEST
Orthocell (OCC) takes the next steps in its license and distribution agreements for its Striate+ dental membrane for bone regeneration.
The exclusive patent and trademark licence agreement and distribution agreement is with Delaware corporation, BioHorizons Implant Systems.
BioHorizons is a global provider of dental implants and tissue regeneration products for dentists and dental specialists, offering products in 90 markets around the world.
Under the contract, Orthocell will grant BioHorizons an exclusive licence of two patent families, covering a collagen scaffold of cell growth, along with a method for producing a collagen membrane.
Orthocell will manufacture and supply BioHorizons with quantities of Striate+ products that embody the licensed IP and will grant the company exclusive distribution rights.
Striate+ is a resorbable collagen membrane used in guided bone and tissue regeneration procedures. The product has been proven to support the transition from two-stage to single-stage dental procedures, reducing the procedure time by several months.
Striate+ is manufactured by Orthocell at its facility in WA, using the company’s proprietary SMRT manufacturing technology.
In consideration of the license granted, Orthocell has received over $21 million in cash.
“We are delighted to have received funds from BioHorizons, solidifying our cash position with $31.23 million on hand as at 20th of July, enabling us to drive the further development of our Remplir nerve product and pipeline of regenerative medicine products,” Managing Director Paul Anderson said.
Orthocell shares were up 3.95 per cent and trading at 39.5 cents at 1:48 pm AEST.